Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells

Author(s): Rosalinda Madonna*, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro*

Journal Name: Current Drug Targets

Volume 18 , Issue 6 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.

Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [719 - 723]
Pages: 5
DOI: 10.2174/1389450117666160401125404
Price: $65

Article Metrics

PDF: 113